Skip to main content

Sigma-Aldrich Q2 Revenues up 3 Percent; Firm Lowers 2013 EPS Guidance

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported a 3 percent increase year over year in its second-quarter revenues as the company beat consensus analyst estimates on the top and bottom lines.

For the three months ended June 30, the company saw revenues climb to $681 million, compared to $664 million a year ago, and beating the average Wall Street estimate of $678.8 million.

In a statement, President and CEO Rakesh Sachdev said that the firm's Research business unit showed "positive and improving organic sales growth." Academic demand in the US was weaker due to sequestration and budget uncertainties, but still improved sequentially from the first quarter.

All segments in Sigma-Aldrich's Applied business unit also grew organically, Sachdev said, led by high-single digit growth in Diagnostics and Testing and low- to mid-single digit growth in Industrial.

SAFC Commercial organic sales grew 2 percent year over year, short of company expectations, due to a "challenging chemical precursor market for the LED industry served by our Hitech segment," he said, adding SAFC Life Science Products saw high-single digit organic sales growth.

Net income for the quarter was $119 million, or $.98 per share, compared to $115 million, or $.94 per share, a year ago. On an adjusted basis, EPS was $1.05, narrowly beating the average analyst estimate of $1.04.

R&D spending shrank 11 percent to $16 million in the quarter, compared to $18 million a year ago, while SG&A spending was trimmed 3 percent to $147 million from $151 million.

Sigma-Aldrich finished the quarter with $562 million in cash and cash equivalents.

Organic sales growth for full-year 2013 is still expected to be in the low- to mid-single digit range, the company said. It lowered adjusted EPS, however, to a new range of $4.05 to $4.15 from an earlier guidance of $4.10 to $4.20 due to incremental changes in foreign currency exchange rates.

Shares of Sigma-Aldrich on the Nasdaq were down 1 percent at $83.07 in morning trading.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.